Gritstone

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期三, 八月 17, 2022
Cyprus Securities and Exchange Commission, Board, Vaccine, Employment, Security (finance), GLOBE, Immune system, Degenerative disease, Pharmaceutical industry, Gritstone

These stock options are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock options are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.
  • Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Retrieved on: 
星期一, 八月 15, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ESMO, U.S. Securities and Exchange Commission, CRC, RNA transfection, GLOBE, European Society for Medical Oncology, Congress, Security (finance), Neoplasm, Patient, DNA, Vaccine, Degenerative disease, Immunotherapy, Circulating tumor DNA, TSNA, Oncology, Fast Track, Colorectal cancer, Food, Immune system, Pharmaceutical industry, Nature Medicine, Gritstone

EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The paper, “Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results,” details results demonstrating that GRANITE generated strong, persistent, and functional tumor-specific CD4+ and CD8+ T cell responses that have potential broad applicability across a range of disease settings. The published data were originally presented at the European Society for Medical Oncology (ESMO) Congress 2021, and acted as the basis for launching two randomized, controlled studies of GRANITE, including a Phase 2/3 trial that has registrational intent (GRANITE-CRC-1L).

Key Points: 
  • The paper, Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results, details results demonstrating that GRANITE generated strong, persistent, and functional tumor-specific CD4+ and CD8+ T cell responses that have potential broad applicability across a range of disease settings.
  • In a tough tumor type such as metastatic colorectal cancer, these data are sufficiently striking to merit publication in Nature Medicine.
  • The first patient was treated in this study in July 2022, and initial results from this study are expected in the second half of 2023.
  • 2) GRANITE-ADJUVANT (NCT05456165), a phase 2 study in patients with high-risk stage II/III colon cancer who are ctDNA+ after definitive surgery.

Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

Retrieved on: 
星期三, 八月 10, 2022
National Institute of Allergy and Infectious Diseases, U.S. Securities and Exchange Commission, HIV/AIDS, Association, American Association, Medical laboratory, RNA transfection, GLOBE, University of Washington Department of Global Health, Diagnosis, National Center for Advancing Translational Sciences, HIV Vaccine Trials Network, HVTN, Cancer, Leadership, Fred Hutchinson Cancer Research Center, National Institute, Infection, Board, Society, Research, NIAID, Security (finance), HSV, Vaccine, COVID-19, HSV-2, Biotechnology, Alumnus, Virology, Degenerative disease, University, Board of directors, HIV, American Association of Clinical Endocrinologists, Immune system, Pharmaceutical industry, Science, Medicine, Director, Gritstone

EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.

Key Points: 
  • EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced the appointment of Lawrence Larry Corey, M.D., to its Board of Directors.
  • Effective August 12, 2022, Dr. Corey replaces Richard Heyman, Ph.D. who stepped down as a Board Member after more than six years of service.
  • I would also like to sincerely thank Rich Heyman for his years of service on Gritstones Board of Directors, where he helped us develop and apply our novel platform technologies.
  • We are thrilled to have Larry join us to help guide continued advancement of Gritstones important clinical programs and unique scientific capabilities, said Dr. Elaine V. Jones, Chair of Gritstone bios Board of Directors.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期二, 七月 26, 2022
Board, Cyprus Securities and Exchange Commission, GLOBE, Employment, Security (finance), Immune system, Vaccine, Degenerative disease, Pharmaceutical industry, Gritstone

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.
  • Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank

Retrieved on: 
星期四, 七月 21, 2022
Silicon, Hercules, GLOBE, CORAL, U.S. Securities and Exchange Commission, NYSE, Immune system, RNA transfection, Cancer, Achievement, Infection, Security (finance), Growth, Vaccine, Degenerative disease, Pharmaceutical industry, Silicon Valley Bank, Gritstone

Establishing this facility reduces our dependence on the capital markets and enables us to focus on executing against our clinical, operational, and strategic goals.

Key Points: 
  • Establishing this facility reduces our dependence on the capital markets and enables us to focus on executing against our clinical, operational, and strategic goals.
  • Under the terms of the $80 million credit facility, $20 million was drawn at closing with an additional $10 million available for drawdown by March 15, 2023.
  • The remaining $50 million becomes available in tranches through June 15, 2024, upon achievement of certain milestones by Gritstone.
  • Capital Advisors Group served as Gritstones financial advisor in connection with the credit facility.

Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022

Retrieved on: 
星期四, 七月 21, 2022
U.S. Securities and Exchange Commission, Second, Webcast, GLOBE, Earnings call, Security (finance), Immune system, Gritstone, Vaccine, Degenerative disease, Pharmaceutical industry

EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the worlds most potent vaccines, announced that it will host a conference call and webcast at 4:30pm ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results, and provide a corporate update.

Key Points: 
  • EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the worlds most potent vaccines, announced that it will host a conference call and webcast at 4:30pm ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results, and provide a corporate update.
  • To access the conference call, dial 800-263-0877 five minutes prior to the start of the call and provide the event title: Gritstone bio Second Quarter 2022 Earnings Call, or the following passcode: 8108859.
  • The archived webcast will be available on Gritstones website at http://ir.gritstonebio.com/investors/events shortly following the conference call and will be available for at least 30 days following the call.
  • Gritstone undertakes no obligation to update or revise any forward-looking statements.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期二, 七月 5, 2022
GLOBE, Immune system, Vaccine, Board, Cyprus Securities and Exchange Commission, Degenerative disease, Employment, Security (finance), Pharmaceutical industry, Gritstone

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.
  • Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications

Retrieved on: 
星期五, 六月 10, 2022
Coalition, Replicon, Program, NIAID, Epitope, LNP, Venezuelan equine encephalitis virus, Immunity, RNA, Coalition for Epidemic Preparedness Innovations, Security (finance), U.S. Securities and Exchange Commission, Infection, Bill & Melinda Gates Foundation, Vaccine, GLOBE, NHP, RNA transfection, COVID-19, Immune system, Epidemic, National Institute of Allergy and Infectious Diseases, Severe acute respiratory syndrome coronavirus 2, Antigen, CEPI, Degenerative disease, CORAL, Immunology, Nature Communications, National Institute, BioRxiv, Gritstone

EMERYVILLE, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced results from a preclinical study evaluating a self-amplifying mRNA (samRNA) vaccine candidate against SARS-CoV-2 were published in Nature Communications, in an article titled “Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection”. The results of the study, which were previously pre-printed in bioRxiv (in November 2021), show that the samRNA vaccine candidate induced broad and potent neutralizing antibodies and T cell immune responses following administration to non-human primates (NHP) at low doses, and that these immune responses were protective against SARS-CoV-2 challenge. Since the pre-publication of these data in November 2021, Gritstone disclosed initial results from a Phase 1 study of a samRNA vaccine candidate demonstrating similar outcomes against SARS-CoV-2 (Press release announcing initial results from CORAL-BOOST study issued on January 4, 2022). The company is currently evaluating samRNA vaccines for coronaviruses and other infectious diseases.

Key Points: 
  • Since the pre-publication of these data in November 2021, Gritstone disclosed initial results from a Phase 1 study of a samRNA vaccine candidate demonstrating similar outcomes against SARS-CoV-2 (Press release announcing initial results from CORAL-BOOST study issued on January 4, 2022).
  • Karin Jooss, Ph.D., Executive Vice President, and Head of R&D added, Self-amplifying mRNA is an attractive platform for potentially superior next-generation mRNA vaccines.
  • Like traditional mRNA vaccines, samRNA vaccines use the host cells transcription system to produce target antigens to stimulate adaptive immunity.
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the worlds most potent vaccines.

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期三, 六月 8, 2022
Vaccine, Board, GLOBE, Security (finance), Degenerative disease, Employment, Cyprus Securities and Exchange Commission, Immune system, Pharmaceutical industry, Gritstone

These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.
  • Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Earns 2022 Great Place to Work Certification™

Retrieved on: 
星期四, 六月 2, 2022
People, Great Places, Trust, Security (finance), U.S. Securities and Exchange Commission, Senior, Vaccine, GLOBE, Certification, Immune system, Culture, Degenerative disease, Workplace, Pharmaceutical industry, Management, Gritstone

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced that the company has been certified as a Great Place to Work by the Great Place to Work Institute.

Key Points: 
  • EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the worlds most potent vaccines, today announced that the company has been certified as a Great Place to Work by the Great Place to Work Institute.
  • We are very proud to receive the designation as a Great Place to Work, said Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone.
  • Great Place to Work is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.
  • Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience.